Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Zhejiang Cheng Yi Pharmaceutical Co Piotroski F-Score Related Terms
Zhejiang Cheng Yi Pharmaceutical Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Cheng Yi Pharmaceutical Co Piotroski F-Score Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Cheng Yi Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Cheng Yi Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Cheng Yi Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Zhejiang Cheng Yi Pharmaceutical Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Zhejiang Cheng Yi Pharmaceutical Co's current Net Income (TTM) was 193.6.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Zhejiang Cheng Yi Pharmaceutical Co's current Cash Flow from Operations (TTM) was 279.1.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Zhejiang Cheng Yi Pharmaceutical Co's return on assets of this year was 0.11523308. Zhejiang Cheng Yi Pharmaceutical Co's return on assets of last year was 0.1138917.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Zhejiang Cheng Yi Pharmaceutical Co's gearing of this year was 0.01345358. Zhejiang Cheng Yi Pharmaceutical Co's gearing of last year was 0.06657531.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Zhejiang Cheng Yi Pharmaceutical Co's current ratio of this year was 1.74464184. Zhejiang Cheng Yi Pharmaceutical Co's current ratio of last year was 1.56480544.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Zhejiang Cheng Yi Pharmaceutical Co's number of shares in issue this year was 442.897. Zhejiang Cheng Yi Pharmaceutical Co's number of shares in issue last year was 457.932.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Zhejiang Cheng Yi Pharmaceutical Co's gross margin of this year was 0.70023062. Zhejiang Cheng Yi Pharmaceutical Co's gross margin of last year was 0.69206175.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Zhejiang Cheng Yi Pharmaceutical Co's asset turnover of this year was 0.49265558. Zhejiang Cheng Yi Pharmaceutical Co's asset turnover of last year was 0.39786001.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
=
9
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Zhejiang Cheng Yi Pharmaceutical Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) has a Piotroski F-Score of 9 as of Aug. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. This is 50% above median its historical median of 6.00. Over the past decade, Zhejiang Cheng Yi Pharmaceutical Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #1 out of 978 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Zhejiang Cheng Yi Pharmaceutical Co's Piotroski F-Score too high?
Zhejiang Cheng Yi Pharmaceutical Co's current Piotroski F-Score of 9 is 50% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Zhejiang Cheng Yi Pharmaceutical Co's value of 9 is 80% above this industry median. Based on the distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #1 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhejiang Cheng Yi Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Cheng Yi Pharmaceutical Co's Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Cheng Yi Pharmaceutical Co ranks #1 out of 978 companies for Piotroski F-Score. This places Zhejiang Cheng Yi Pharmaceutical Co in the top 0% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Zhejiang Cheng Yi Pharmaceutical Co's value of 9 is 80% above this benchmark. Historically, Zhejiang Cheng Yi Pharmaceutical Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Zhejiang Cheng Yi Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Cheng Yi Pharmaceutical Co's current Piotroski F-Score of 9 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Zhejiang Cheng Yi Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Cheng Yi Pharmaceutical Co's current Piotroski F-Score is 9, which is 50% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Cheng Yi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥8.45, compared to a current price of ¥7.43 — trading 12.1% below its estimated fair value. The current Piotroski F-Score is 9, which is 50% above median its 10-year median of 6.00 and 80% above the Drug Manufacturers industry median of 5.00. Zhejiang Cheng Yi Pharmaceutical Co's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811), the current Piotroski F-Score is 9 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Cheng Yi Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥7.43 is trading 12.1% below its estimated GF Value™ of ¥8.45.
GuruFocus considers Zhejiang Cheng Yi Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603811:
Piotroski F-Score: 9 (50% above median its 10-year median of 6.00)
GF Value™: ¥8.45 vs. price of ¥7.43 (12.1% below fair value)
Industry Position: 80% above the Drug Manufacturers median (#1 of 978)
No single metric tells the full story. See the SHSE:603811 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.
85GF Score
Get the complete analysis for SHSE:603811
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603811 has been successfully added to your 
